Mitotane116. Decker RA, Kuehner ME 1991 Adrenocortical carcinoma. Surg 57: 502 513 Remond S, Bardet S, Charbonnel B 1992 [Complete and lasting remission of a metastatic malignant adrenocortical carcinoma under treatment with OPDDD alone]. Presse Med 21: 865 118. Ilias I, Alevizaki M, Philippou G, Anastasiou E, Souvatzoglou A 2001 Sustained remission of metastatic adrenal carcinoma during long-term administration of low-dose mitotane. J Endocrinol Invest 24: 532535 119. Allolio B, Hahner S, Weismann D, Fassnacht M 2004 Management of adrenocortical carcinoma. Clin Endocrinol Oxf ; 60: 273287 120. van Slooten H, Moolenaar AJ, van Seters AP, Smeenk D 1984 The treatment of adrenocortical carcinoma with o, p -DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 20: 4753 121. Haak HR, Hermans J, van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ, Krans HM 1994 Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 69: 947951 122. Baudin E, Pellegriti G, Bonnay M, Penfornis A, Laplanche A, Vassal G, Schlumberger M 2001 Impact of monitoring plasma 1, 1-dichlorodiphenildichloroethane o, p DDD ; levels on the treatment of patients with adrenocortical carcinoma. Cancer 92: 13851392 123. Heilmann P, Wagner P, Nawroth PP, Ziegler R 2001 [Therapy of the adrenocortical carcinoma with Lysodren o, p'-DDD ; . Therapeutic management by monitoring o, p -DDD blood levels]. Med Klin 96: 371377 124. Seki M, Nomura K, Hirohara D, Kanazawa M, Sawada T, Takasaki K, Demura H 1999 Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma. Endocr Relat Cancer 6: 529 533 Terzolo M, Pia A, Berruti A, Osella G, Ali A, Carbone V, Testa E, Dogliotti L, Angeli A 2000 Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J Clin Endocrinol Metab 85: 2234 2238 Hutter Jr AM, Kayhoe DE 1966 Adrenal cortical carcinoma. Results of treatment with o, p DDD in 138 patients. J Med 41: 581592 127. Schteingart DE, Motazedi A, Noonan RA, Thompson NW 1982 Treatment of adrenal carcinomas. Arch Surg 117: 11421146 128. Lanser JB, van Seters AP, Moolenaar AJ, Haak HR, Bollen EL 1992 Neuropsychologic and neurologic side effects of mitotane and reversibility of symptoms. J Clin Oncol 10: 1504 129. Bollen E, Lanser JB 1992 Reversible mental deterioration and neurological disturbances with o, p -DDD therapy. Clin Neurol Neurosurg 94 Suppl ; : S49 S51 130. Hague RV, May W, Cullen DR 1989 Hepatic microsomal enzyme induction and adrenal crisis due to o, p DDD therapy for metastatic adrenocortical carcinoma. Clin Endocrinol Oxf ; 31: 5157 131. Bertagna C, Orth DN 1981 Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center 1951 to 1978 ; . J Med 71: 855 875 Stojadinovic A, Ghossein RA, Hoos A, Nissan A, Marshall D, Dudas M, Cordon-Cardo C, Jaques DP, Brennan MF 2002 Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 20: 941950 133. Dickstein G 1999 Is there a role of low dose of mitotane as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab 84: 1488 1489 Dickstein G, Shechner C, Arad E, Best LA, Nativ O 1998 Is there a role for low doses of mitotane o, p -DDD ; as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab 83: 3100 3103 Vassilopoulou-Sellin R, Guinee VF, Klein MJ, Taylor SH, Hess KR, Schultz PN, Samaan NA 1993 Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 71: 3119 3123 Ahlman H, Khorram-Manesh A, Jansson S, Wangberg B, Nilsson O, Jacobsson CE, Lindstedt S 2001 Cytotoxic treatment of adrenocortical carcinoma. World J Surg 25: 927933 137. Berruti A, Terzolo M, Sperone P, Pia A, Casa SD, Gross DJ, Carnaghi C, Casali P, Porpiglia F, Mantero F, Reimondo G, Angeli A, Dogliotti L 2005 Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of ad.
Of adrenocortical cancer with o, p'DDD. Ann Intern Med 1960; 53: 672-82. Luton JP, Cerdas S, Billaud L et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990; 322: 1195-201. Karakousis CP, Rao U, Moore R. Adrenal adenocarcinomas: Histologic grading and survival. J Surg Oncol 1985; 29: 105-11. Boven E, Vermorken JB, van Slooten H, Pinedo HM. Complete response of metastasized adrenal cortical carcinoma with o, p'DDD. Case report and literature review. Cancer 1984; 53: 26-9. Lubitz JA, Freeman L, Okun R. Mitotane use in inoperable adrenal cortical carcinoma. JAMA 1973; 223: 1109-12. Wajchenberg BL, Albergaria Pereira MA, Medonca BB et al. Adrenocortical carcinoma: Clinical and laboratory observations. Cancer 2000; 88: 711-36. Barzon L, Fallo F, Sonino N et al. Adrenocortical carcinoma: Experience in 45 patients. Oncology 1997; 54: 490-6. Vassilopoulou-Sellin R, Guinee VF, Klein MJ et al. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 1993; 71: 3119-23. Kasperlik-Zaluska AA, Migdalska BM, Makowska AM. Incidentally found adrenocortical carcinoma. A study of 21 patients. Eur J Cancer 1998; 34: 1721-4. Kasperlik-Zaluska AA, Migdalska BM, Zgliczynski S, Makowska AM. Adrenocortical carcinoma. A clinical study and treatment results of 52 patients. Cancer 1995; 75: 2587-91. Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery 1992; 112: 963-70 discussion 970-1 ; . Schteingart DE, Motazedi A, Noonan RA, Thompson NW. Treatment of adrenal carcinomas. Arch Surg 1982; 117: 1142-6. Tjalve H, Wilander E and Johansson EB. Distribution of labeled streptozotocin in mice: Uptake and retention in pancreatic islets. J Endocrinol 1976; 69: 455-6. Eriksson B, Oberg K, Curstedt T et al. Treatment of hormoneproducing adrenocortical cancer with o, p'DDD and streptozocin. Cancer 1987; 59: 1398-403. Muller J. Adrenocortical tumors: Clinical and diagnostic findings. Results Cancer Res 1990; 118: 106-12. Nader S, Hickey RC, Sellin RV, Samaan NA. Adrenal cortical carcinoma. A study of 77 cases. Cancer 1983; 52: 707-11. MacFarlane DA. Cancer of the adrenal cortex: The natural history, prognosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl 1958; 23: 155-86. Sullivan M, Boileau M, Hodges CV. Adrenal cortical carcinoma. J Urol 1978; 120: 660-5. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva: WHO 1979. Bertagna C, Orth DN. Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center 1951-1978 ; . J Med 1981; 71: 855-75. Didolkar MS, Bescher RA, Elias EG, Moore RH. Natural history of adrenal cortical carcinoma: A clinicopathologic study of 42 patients. Cancer 1981; 47: 2153-61. van Slooten H, Moolenaar AJ, van Seters AP, Smeenk D. The treatment of adrenocortical carcinoma with o, p'-DDD: Prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 1984; 20: 47-53. Mitotane informationEffectively be implemented throughout the whole of that technical infrastructure, namely, the DNS. 26. The efficiency with which policy can be implemented through the deployment of the technical infrastructure, however, also inspires caution. New law has, in the past, been created in democracies by representative legislatures. It is one thing to give expression to existing law in an effective manner through the deployment of a powerful technical infrastructure. It is quite another thing to use the technical infrastructure not merely for the implementation, but also for the formulation, of new laws. 27. The second option remains the classical option of the international system, the treaty. The disadvantages of the treaty in the context of a medium that changes rapidly and radically like the Internet are apparent. Multilateral treaties take years to negotiate, and years to bring into effect across any widespread geographical area. The machinery for revising them is also usually equally as cumbersome. On the other hand, treaties are negotiated by legitimately empowered representatives of elected governments and are given effect usually only after ratification by the elected government. 28. The limitations of the two existing options are apparent. Those limitations call for a concerted effort to find the means of allowing social processes to be as innovative, subtle and beneficial as the technological processes that have provoked the challenges which the social processes are called upon to address. Discount DrugsMitotane reviewUNIVERSITY OF LIMERICK, A vascular graft. 23 March 2005. Int. Cl. 2006 ; A61F 2 06. TMC125 800 mg twice daily was generally safe and well-tolerated when given to HIV + adults receiving stable regimens including LPV RTV, SQV, and NRTIs. LPV Cmax and AUC12h were statistically significantly decreased, but LPV Cmin and PK parameters for RTV and SQV did not change significantly after 2 weeks coadministration with TMC125. The observed changes in plasma PI levels were of small magnitude 11-24% ; and unlikely to be clinically significant. TMC125 PK results were comparable to those when co-administered with a single ritonavir-boosted PI historical controls and moxifloxacin. Subthreshold depressions: clinical and polysomnographic validation of dysthymic, residual and masked forms. Journal of Affective Disorders, 45, 53 63. Disorders, 45. Lipinski CA, L. F., Dominy BW, Feeney PJ. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings ADV DRUG DELIVER REV 23: 3-25 and mrv. Because of the considerable interest of so many HIVers in this possible therapy to reverse facial wasting, I personally went to Tijuana, Mexico, to see the procedure done on a half dozen people who agreed to participate in a small trial, and was extremely impressed by the results. The surgeons doing the injections seemed very skilled, in general, and already proficient in this particular procedure. They have been using it for a couple of years for eliminating wrinkles and other cosmetic work in non-HIVers, and are using a modified technique in essence, the one developed by Patrick Amard, the Parisian surgeon who got the impressive results in the small trial discussed above ; for the lipo-associated wasting. I will be returning soon to see the third treatment for the six HIVers participating in this Mexico trial. Three of them had some of the very worst facial wasting I've ever seen so their results should definitely tell the tale. But so far this looks like an amazing success for reversing the facial wasting. The level of discomfort during the injections seemed similar to what Robinson reported, and none of the six people I watched found it unbearable, although there was definitely some pain at times. And yes, indeed, we all went out to dinner that night and had a grand time. The PLA is far less expensive than other approaches being tried in the US. A San Diego dermatologist went with us to observe and said that she was very impressed by the results, and that the fees shown on the surgeon's list were less than a third what people would pay with most US docs. She also noted that the cost of PLA was staggeringly less than that of substances like collagen. At the clinic in Mexico, the total fee for three visits, including the drug, the surgeon's fees, and the clinic costs, is around 50 but efforts are underway to reduce that price. I know that many people would prefer to have their local dermatologist or cosmetic surgeon do the procedure. The problem appears to be the need for specific training in how to do it. After observing the six procedures, I can tell you that it was clear to me that you would need someone very experienced in aesthetic facial procedures, in general, and specifically trained in the use of the polylactic acid substance. It is apparently difficult to inject because of thickness, etc., and it requires insertion in precise places to achieve the desired effect. Unlike collagen or other implanted substances, this is not a case of just sticking in a filler material where you can immediately see the results. Instead, you're getting injections of the PLA that will, over the course of several weeks, prompt your own body to produce collagen in those locations. It's that locally produced collagen that will actually create the change. Thus, the end result depends on the surgeon being able to predict the likely results if X amount is injected in Y location, and how to fine tune the injections accordingly. I know that while I was watching the procedures I thought to myself "Gee, I wouldn't want to be first in line for this." Although I very hopeful that we can get US dermatologists and cosmetic surgeons interested in receiving training to do this procedure which is being offered at the Mexican clinics for any doc who is interested ; , I concerned about surgeons or dermatologists who have NOT been specifically trained in the use of PLA just attempting it on their own. When I was researching the article on this that I wrote for POZ Magazine June 2001 ; , the only negative stories I heard came from people who used a local US doc who had never before used the substance. Obviously, there may be some US docs who already know the techniques but that's definitely a question you'd want to ask. It appears that for now many people are planning on taking advantage of the expertise of the Mexican surgeons and getting the procedures done there. The surgeons whom I observed doing the procedures have practices in Reynosa, Mexico, and Tijuana, Mexico the latter of which will be easier for most people since you can fly into San Diego ; . The clinic where I observed the surgeries was in Tijuana and the surgeons were Jorge Tagle, MD, and Guillermo Hernandez, MD. Both are very experienced in the procedure and have so far gotten great results in people with lipo-associated facial wasting. Dr. Tagle speaks more fluent English and is willing to discuss the procedure with US docs or patients with concerns. If you are interested in setting up an appointment to have the procedures done, do remember that you have to have a minimum of at least three treatments, spaced three weeks apart. So that means three trips to San Diego and three hops across the border take your passport as technically you need it although they don't seem to usually ask ; . And again, for those with really severe wasting, additional treatments may be necessary. D.1 b ; Situations where the IMP to be used in the CT has a MA in the MS concerned but the protocol allows that any brand of the IMP with a MA in that MS be administered to the trial subjects and it is not possible to clearly identify the IMP s ; in advance to the trial start : In the protocol, is treatment defined only by active substance? - if yes, go to D2 In the protocol, treatment regimens allow different combinations of marketed products used according to local clinical practice at some or all investigator sites in the MS. - if yes, go to D2. The products to be administered as IMPs are defined as belonging to an ATC group6. - if yes give the ATC group level 3 or more to the level that can be defined ; of the applicable authorised codes in the ATC code field in D.2 of this form Other : - if yes, please specify and multivitamin. In most patients with chronic hepatitis C. "the value of pre-treatment liver biopsy outweighs its risks and mitotane. Simulation is also shown in Fig. 11 dashed line ; , using the relaxation constant G obtained above. The diffusion constant is found to be D9 0.02 nm2 ns, which is at least of the same order of magnitude as the result from CG MD simulation. The LG dynamics can therefore capture some aspects of the CG MD phase-separation dynamics without further theoretical improvements, which are in progress. DISCUSSION AND CONCLUSIONS In this article, a mesoscopic model based on the LandauGinzberg free energy theory was constructed to characterize the liquid-gel phase separation of binary mixed lipid bilayers. The parameters in the mesoscopic model are bridged in a multi-scale fashion from CG MD simulation data. It is found that the mesoscopic model reproduces the equilibrium properties of the liquid-gel phase-separation system quite well. An implication from this result is that when only equilibrium properties are considered, or when there is a separation of timescales where the phase-separation dynamics reaches equilibrium faster than other dynamical variables, the mesoscopic model using a Landau-Ginzberg free energy theory can be very useful. Although the phenomenological dynamics using the LG dynamics is not quite able to capture the multi-timescale motion of the order parameter field, it is able to reproduce some slow motion behavior of the phaseseparation dynamics such as the phase boundary diffusive motion. This result is also encouraging since the long timescale dynamics is usually more important to model large lengthscale objects such as vesicles. Further work along these lines, and to improve the accuracy of the mesoscopic dynamical model, is in progress. The main goal of this article was to find a practical multiscale approach for bridging a mesoscopic model of phase separation in mixed lipid bilayers with a more detailed and murine. Mitotane side effectsMitogane, m8totane, mmitotane, mit9tane, mirotane, nitotane, mititane, mitotzne, mitoane, miitotane, mutotane, mitotanw, mitotanee, mittane, itotane, miyotane, mitotnae, mito5ane, mitltane, mittotane, mitofane, mitotand, mitotwne, mototane, mi6otane, mi5otane, mitotxne, mitotan, mitoatne, mktotane, mitotame, miotane, mitotaane, miottane. |
|